MDT-AP-3311
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 5.1
- sex
- M
- new_clusters
- C6
- umap1_2d
- 2.449849658
- umap2_2d
- 5.970508217
- umap1_3d
- 1.505339556
- umap2_3d
- -1.49927153
- umap3_3d
- -4.956748185
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.440
- MITOTIC_SPINDLE+0.410
- G2M_CHECKPOINT+0.350
- E2F_TARGETS+0.300
- ANDROGEN_RESPONSE+0.220
- TGF_BETA_SIGNALING+0.190
- MYC_TARGETS_V1+0.180
- PI3K_AKT_MTOR_SIGNALING+0.170
- HEME_METABOLISM+0.140
- UV_RESPONSE_DN+0.140
Top 10 suppressed
- COAGULATION-0.440
- INTERFERON_ALPHA_RESPONSE-0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.410
- ALLOGRAFT_REJECTION-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- IL6_JAK_STAT3_SIGNALING-0.370
- CHOLESTEROL_HOMEOSTASIS-0.360
- KRAS_SIGNALING_DN-0.360
- INFLAMMATORY_RESPONSE-0.350
- MYOGENESIS-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3021 | Med | Medulloblastoma | 0.912 |
| 2 | MDT-AP-3288 | Med | Medulloblastoma | 0.907 |
| 3 | ERR2598089 | fetal | fetal | 0.906 |
| 4 | MDT-AP-3325 | Med | Medulloblastoma | 0.903 |
| 5 | SJEPD030795_D2.RNA-Seq | EPN | Posterior Fossa EPN | 0.880 |
| 6 | SRR9879265 | — | cohortMD1 | 0.879 |
| 7 | TCGA-E9-A1R7-01A-11R-A14M-07 | — | B | 0.879 |
| 8 | MDT-AP-3307 | Med | Medulloblastoma | 0.879 |
| 9 | SRR661290 | GTEX | — | 0.878 |
| 10 | TCGA-C8-A12M-01A-11R-A115-07 | — | B | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.440 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.070 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.060 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |